MicroRNA 675-5p (miR-675-5p) (miR-675-5p)

MicroRNA 675-5p (miR-675-5p) is a small non-coding RNA molecule that is processed from the first exon of the long non-coding RNA H19 (PMID: 21750012). It serves as a critical post-transcriptional regulator by binding to the 3' untranslated regions (UTRs) of specific target mRNAs, such as the Retinoblastoma (RB1) tumor suppressor and GATA2, leading to their downregulation (PMID: 25242301). In many clinical contexts, particularly oncology, miR-675-5p acts as an oncomiR, where its overexpression is linked to increased cell proliferation, migration, and invasion in colorectal, gastric, and lung cancers (PMID: 24607834). Beyond its role in malignancy, miR-675-5p is essential for physiological processes including skeletal muscle regeneration and the maintenance of cartilage homeostasis, with dysregulation contributing to osteoarthritis (PMID: 27045457). While there are currently no FDA-approved therapies targeting this molecule, it is a subject of intense research using antisense oligonucleotides (antagomirs) to inhibit its oncogenic activity or synthetic mimics to restore its function in degenerative diseases (PMID: 30106353). The therapeutic development of miR-675-5p modulators faces challenges common to RNA therapeutics, including the need for stable delivery systems and the mitigation of off-target effects.

Other names

hsa-miR-675-5pmiR-675MicroRNA 675H19-derived microRNA 675

Binds to the 3' untranslated region (UTR) of target messenger RNAs (mRNAs) to induce translational repression or mRNA degradation via the RNA-induced silencing complex (RISC).